Inflammatory autoimmune diseases (rheumatoid arthritis, ankylosing
INTRODUCTION
Rheumatoid arthritis (RA), ankylosing spondylitis (AS), Crohn's disease, ulcerative colitis (UC), psoriasis, and psoriatic arthritis (PsA) are inflammatory autoimmune diseases.
These conditions are generally chronic and lifelong, characterized by alternating flare-ups and periods of remission. Given their chronic, and often progressive, nature, they have a considerable impact on patients' quality of life [1] [2] [3] [4] [5] as well as healthcare budgets [6] [7] [8] [9] [10] .
First-line treatments include non-steroidal anti-inflammatory drugs (NSAIDs), conventional disease-modifying anti-rheumatic drugs (cDMARDs; e.g., methotrexate), and topical and/or local corticosteroids;
immunosuppressants and systemic corticosteroids are also used [11] [12] [13] [14] [15] [16] . Inhibitors of tumor necrosis factor alpha (TNF-a) have shown good efficacy and an acceptable safety profile in patients after failure of conventional treatments, and in those patients with contraindications to conventional treatments [17] [18] [19] [20] . TNF-a inhibitors are biologics, which are defined as medicines that are produced by cells (ranging from bacterial cells or yeast, to murine or human cell lines), or derived from a biological source. Infliximab (Remicade Ò ; Janssen Biotech, Inc.) was granted marketing authorization in 1999 [21] . It is a monoclonal antibody and TNF-a inhibitor, indicated in the areas of RA, AS, adult and pediatric Crohn's disease, adult and pediatric UC, psoriasis, and PsA [21] . The efficacy and safety of infliximab in these disease areas is supported by extensive clinical evidence [16, [22] [23] [24] [25] [26] . Biosimilar infliximab (Remsima Ò ; Celltrion, Inc.) is a biosimilar of Remicade.
Biosimilars, in contrast to generics, do not have to be identical to the innovator and/or brand product. The intrinsic complexity of the molecule and their biological derivation means that it is not possible to produce exact copies of the reference product. Biosimilars must demonstrate similarity to the reference product in terms of quality, biological activity, clinical efficacy, and safety [27] [28] [29] . Remsima was authorized in 2013 by the European Medicines Agency (EMA) for the same indications as the reference product Remicade [30] . Remsima was the first biosimilar antibody to meet the stringent EMA criteria for extrapolation of indications [31] [32] . The pharmacokinetic profiles of Remsima and Remicade were demonstrated to be equivalent [30, 32, 33] . The trials also concluded that Remsima was well tolerated, with an efficacy and safety profile comparable to that of Remicade up to week 30 [30, 32, 33] . These 30-week results have been confirmed by 54-week data and 2-year follow-up extension studies [34] [35] [36] [37] . Biologics, including TNF-a inhibitors, are costly compared with cDMARDs and have led to increased costs to healthcare systems [38] .
Remicade has been the subject of several economic analyses (in different disease areas and countries) [39] [40] [41] [42] [43] [44] . The results indicate that
Remicade might be cost-effective in some patient groups, but appears unlikely to be cost-effective in others. Furthermore, even in cases where Remicade is cost-effective, any savings made are insufficient to offset the additional drug-acquisition and administration costs [45, 46] Musculoskeletal Health in Europe Report v5 [58] . A mean value of the range given (derived from published literature) was used c Taken from [59] , supported by [60] . The consistent data from two such different locations suggest that this incidence rate is likely to be consistent across North America and Europe d The incidence for Germany and the UK was assumed to be the same as for The Netherlands e For these countries, the incidence was calculated from the UK incidence, weighted based on the prevalence in the respective country f Including one loading dose g The SPC indicated that maintenance doses should be administered every 6-8 weeks; therefore, 7 weeks was used for the purpose of this model h Data from The Netherlands were used as proxy literature, and country-specific data were applied if possible ( Table 2 ). In the absence of country-specific incidence data, data were derived from other studies, and assumptions regarding the generalizability and appropriateness of these data were made (Table 2) . It was assumed in the model that all patients present at the beginning of the forecast year, with costs reflecting treatment for a year.
Selection of incidence and prevalence data was based upon the limited available published evidence. For consistency, where possible, prevalence rates were taken from the same source.
The percentages of patients treated with any medication (i.e., biological [b]DMARDs or cDMARDs) for their condition (termed 'drug-treated patients') are presented in 
Uptake of Remsima
The uptake of Remsima (expressed as the proportion of patients receiving Remsima who would otherwise have received Remicade) was estimated at 25% in the switch and 50% in the naïve populations. The difference in values was adopted to reflect that uptake is likely to be greater in treatment-naïve patients compared with patients who could potentially switch, because patients already receiving Remicade might be more likely to stay on their existing therapy compared with those initiating infliximab therapy. In our model, there was a linear relation between uptake and budget impact (i.e., doubling the uptake from 50% to 100% would double the budget impact). Therefore, the impact of changes in uptake could be easily inferred, but has not been investigated in a sensitivity analysis.
Costs
The country-specific list prices for Remicade used in the model are shown in Table 1 . monitoring, and adverse events) were assumed to be the same for Remicade and Remsima [30] .
The analysis in this article was based on previously conducted studies, and did not involve any new studies of human or animal subjects performed by any of the authors.
Model Structure and Equations

Patient Numbers
The total number of patients being treated with either Remsima or Remicade was defined as:
where q is total number of patients (treated with either Remicade or Remsima); a is number of patients treated with Remicade in the model; b
is number of patients treated with Remsima in the model.
The variables a and b were calculated as follows:
where i is countries selected in the model; j is indications selected in the model; p ij is total population of indication j in country i; a ij for switch patient group: prevalence of indication j in country i, for treatment-naïve patient group:
incidence of indication j in country i ( Table 2) ; b ij is proportion of patients treated with drugs for indication j in country i; c ij is proportion of drug-treated patients treated with Remsima indication j in country i.
For the purpose of this budget impact model, it was assumed that the total patients q was constant in both scenarios (introducing Remsima or not introducing it), that is, patients switching to Remsima always did so from Remicade. This assumption was made to enable direct comparison of cost difference between the two scenarios.
Patient Costs
The total cost per patient was calculated as: The budget impact h was calculated as: ðqÁcÞ À ðaÁc þ bÁdÞ:
Sensitivity Analyses
Sensitivity analyses were conducted to assess the robustness of results. Parameters varied in the sensitivity analysis included the number of patients treated with Remicade (±10%), prevalence estimates (±10%), incidence estimates (±10%), and patient's weight (±5 kg). Parameters were varied for both the 'switch' and naïve population groups within the specified ranges for each of the indications of interest. The analyses were performed for each of the three discount scenarios.
RESULTS
Assuming that Remsima would be available at a price that is between 10% and 30% less than that of Remicade, the annual drug cost savings that could be made through the introduction of Remsima across the six licensed disease areas were projected to range from €2.89 million in Belgium (10% discount scenario) to €33.80 million in Germany (30% discount scenario) ( Table 4 ) (for infliximab-naïve and switch patients combined). The cumulative drug cost savings across the five countries included (Germany, the UK, Italy, the Netherlands, and Belgium) and the six licensed disease areas were projected to range from €25.79 million (10% discount) to €77.37 million (30% discount). Detailed projected drug cost savings by disease area and country are shown in Table 4 . If such savings were made and used to treat additional patients with Remsima, the number of additional patients that could be treated across the six disease areas ranged from 250 in Belgium (10% discount scenario) to 2602 in Germany (30% discount scenario) ( Table 5 ). Detailed results for estimated numbers of additional patients that could be treated with Remsima are shown in Table 5 .
Sensitivity Analyses
Tornado diagrams for the one-way sensitivity analyses are shown in Fig. 1 (for the 10% discount scenario), Fig. 2 (for the 20% discount scenario), and Fig. 3 (for the 30% discount scenario). As would be expected, any changes have the lowest impact in the 10% discount scenario and the highest impact in the 30% discount scenario. Of the four parameters explored in the sensitivity analysis, the percentage of patients treated with Remicade (i.e., the total number of patients considered in the model) had the biggest impact, because an increase or decrease in this parameter would translate directly and linearly into the projected savings (i.e., a 10% increase in patients being treated with Remicade or [49] . If this is the case, our analysis showed that there is the potential for additional patients to be treated with Remsima.
CONCLUSION
The introduction of Remsima could lead to drug cost-related savings across Germany, the UK, Italy, the Netherlands, and Belgium. A less-costly brand of infliximab might also lead to wider patient access and, therefore, improved patient outcomes. 28. European Medicines Agency. Questions and answers on biosimilar medicines (similar
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